bpc 157 safety research bpc-157 human use and the Difference Between an Evidence Gap and a Cover bpc-157 safety study human evidence

Determining the right dosage and frequency is crucial for achieving the best results

Cad Pesqui

The Pernicious Anaemia Society is getting frequent worried phone calls from members desperate that their B12 injections have been postponed due to the coronavirus crisis

The good news is that GHK-Cu is generally considered very safe and is well-tolerated by most people

No mixing

Pre-Blend Weekly Schedule Example Pre-blend dose at each titration step Phase Start Weeks 1-4 Draw Volume 0.40 mL (40 units) Reta Delivered 2.0 mg Cag Delivered 0.4 mg Phase Step 1 Weeks 5-8 Draw Volume 0.60 mL (60 units) Reta Delivered 3.0 mg Cag Delivered 0.6 mg Phase Step 2 Weeks 9-16 Draw Volume 0.80 mL (80 units) Reta Delivered 4.0 mg Cag Delivered 0.8 mg Phase Step 3 Weeks 17-20 Draw Volume 1.20 mL (120 units) Reta Delivered 6.0 mg Cag Delivered 1.2 mg Phase Step 4 Weeks 21-24 Draw Volume 1.60 mL (160 units) Reta Delivered 8.0 mg Cag Delivered 1.6 mg Phase Maintenance Weeks 25+ Draw Volume 2.40 mL (240 units) Reta Delivered 12.0 mg Cag Delivered 2.4 mg One injection per week